摘要
降低低密度脂蛋白胆固醇(LDL-C)一直是减少和预防动脉粥样硬化性(AS)心血管疾病的主要手段,前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂可显著降低LDL-C水平并减少心血管相关事件发生。同时,PCSK9抑制剂可促进AS斑块消退,其通过降低脂蛋白a水平、改善内皮细胞功能、减轻炎性反应、抑制血小板活化等途径发挥抗AS作用。该文就PCSK9抑制剂对AS斑块的影响及其抗AS作用机制进行综述,以期更全面了解PCSK9抑制剂作用,从而为PCSK9抑制剂的临床应用提供参考。
Reducing low-density lipoprotein cholesterol(LDL-C)has always been the main means to reduce and prevent atherosclerotic(AS)cardiovascular diseases.Proprotein convertase subtilisin kexin type 9(PCSK9)inhibitors can significantly reduce LDL-C and reduce cardiovascular related events.At the same time,PCSK9 inhibitors can promote the regression of atherosclerotic plaques,and play an anti-AS role by reducing lipoprotein a,improving endothelial cell function,reducing the inflammatory response,and inhibiting platelet activation.In this paper,the effects of PCSK9 inhibitors on AS plaques and their anti-AS mechanism were reviewed to understand the role of PCSK9 inhibitors more comprehensively and provide a reference for the clinical application of PCSK9 inhibitors.
作者
雷浩浩(综述)
陈运清(审校)
LEI Haohao;CHEN Yunqing(Department of Cardiolgy,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处
《现代医药卫生》
2023年第16期2817-2821,共5页
Journal of Modern Medicine & Health
